Searchable abstracts of presentations at key conferences in endocrinology

ea0056p356 | Diabetes (to include epidemiology, pathophysiology) | ECE2018

Diabetes after liver transplantation

Moreno-Moreno Paloma , Barrera-Martin Ana , Munoz-Jimenez Concepcion , Rosa Alhambra-Exposito Maria , Angeles Galvez-Moreno Maria

Objective: Diagnosis of diabetes after transplantation (NODAT) has been described in up to 25% of cases. NODAT is a metabolically complex disorder, similar to type 2 diabetes. Factors that influence the development of NODAT are: BMI, HCV and immunosuppression. Objective: to know the prevalence and incidence of diabetes mellitus (DM) in liver transplant patients of our hospital.Patients and methods: Retrospective descriptive study of liver transplant pati...

ea0041gp46 | Bone & Calcium Homeostasis (1) | ECE2016

Denosumab increases bone mineral density in primary hyperparathyroidism treated with cinacalcet

Munoz Jimenez Concepcion , Manuel Quesada Gomez Jose , Moreno Moreno, Maria Rosa Alhambra Exposito Paloma , Inmaculada Prior Sanchez Maria , Angeles Galvez Moreno Maria

Cinacalcet decreases and normalizes serum calcium levels across a broad severity range of primary hyperparathyroidism (PHPT), slightly reduces parathyroid hormone levels which generally remains elevated, whereas it has no effect on bone mineral density (BMD). Therefore, when administering cinacalcet to a patient with PHPT, concomitant treatment with an anti-catabolic drug should be considered.An open-labeled, prospective trial was conducted in 32 patient...

ea0073aep132 | Calcium and Bone | ECE2021

Bone mineral density evolution after Denosumab withdrawal

Mª Rosa Alhambra Expósito , Ana Barrera-Martín , Ángel Rebollo-Román , José Manuel Quesada Gómez , Maria Angeles Galvez Moreno

IntroductionDenosumab (Dab) withdrawal is associated with a quick loss in bone mineral density (BMD) and a high risk of multiple vertebral fractures. It is still not stablished which strategy best prevents BMD loss after Dab discontinuation.AimCompare the use of bisphosphonates for one year after Dab withdrawal versus a tapering Dab regimen in terms of BMD and fracture occurrence.Method...

ea0073aep241 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

GLP-1 receptor agonists and bariatric surgery in nonalcoholic steatohepatitis

Soraya León , María Dolores Alcántara-Laguna , Maria José Molina , Alfonso Jesús Calañas Continente , Concepción Muñoz , Maria Angeles Galvez Moreno , Aura D. Herrera-Martínez

RationaleObesity is associated with multiple comorbidities including nonalcoholic steatohepatitis (NASH). Despite its association with increased morbidity and mortality, treatment options are limited. Some studies have suggested that glucagon-like peptide-1 receptor agonists (aGLP-1) are associated with NASH resolution. Additionally, the effects of bariatric surgery on NASH-associated liver fibrosis are controversial.Methods<p ...

ea0073pep9.6 | Presented ePosters 9: Endocrine-Related Cancer | ECE2021

Characterization of signaling pathways and molecular mechanisms underlying kisspeptin response in pancreatic neuroendocrine tumor (panNETs) cells

Antonio C Fuentes-Fayos , Emilia Alors-Pérez , Sergio Pedraza Arévalo , Aura D. Herrera-Martínez , Jose Angel Días-Pérez , Teresa Caro , MARIA Angeles Galvez Moreno , Raul M Luque , Antonio Jesús Martínez-Fuentes

Pancreatic neuroendocrine tumors (panNETs) comprise several neoplasms in which a precise diagnosis and therapeutic treatment are hampered by their diversity and heterogeneity which in turn, hind the identification of common molecular signatures and the development of efficient therapeutic approaches. Subsequently, there are no clinical, biochemical, anatomopathological, immunohistochemical or molecular features capable to currently predict either tumor prognosis or post-surgic...